{"title":"持续抑郁症状轨迹预测从轻度认知障碍到阿尔茨海默病的转变:一项纵向ADNI研究。","authors":"Xiahao Ding, Zhiying Zheng, Haitong Wang, Yuanzhen Shao, Shouqiang Zhu, Zhengliang Ma, Xiaoping Gu, Tianjiao Xia","doi":"10.1016/j.jad.2025.120066","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Depressive symptoms are increasingly recognized as a modifiable risk factor for Alzheimer's disease (AD). However, most studies have assessed these symptoms at a single time point or within overlapping symptom-outcome windows, limiting temporal inference.</p><p><strong>Methods: </strong>We analyzed 397 participants with baseline mild cognitive impairment (MCI) from the Alzheimer's Disease Neuroimaging Initiative. Depressive symptoms were measured with the 15-item Geriatric Depression Scale (GDS). Group-based trajectory modeling classified symptom courses over the first 36 months. Cox proportional-hazards models estimated the risk of MCI-to-AD conversion over a maximum follow-up of 156 months after the landmark. Restricted cubic spline analysis evaluated the dose-response relationship between 36-month GDS scores and conversion hazard.</p><p><strong>Results: </strong>Three distinct trajectories emerged: persistently low, moderate, and high depressive symptoms. Compared with the low-symptom group, the moderate-symptom group had an adjusted hazard ratio (HR) of 2.36 (95 % CI 1.35-4.13; p = 0.003), and the high-symptom group an HR of 3.79 (95 % CI 1.86-7.69; p < 0.001). A two-group split (low vs. high) produced an adjusted HR of 1.98 (95 % CI 1.25-3.13; p = 0.003). Spline analysis confirmed a linear, dose-response association: each one-point increase in 36-month GDS corresponded to a proportional rise in hazard (p < 0.001).</p><p><strong>Limitations: </strong>The GDS is self-reported and not a clinical diagnosis.</p><p><strong>Conclusions: </strong>Persistently high depressive symptoms over 36 months after MCI diagnosis provide robust prognostic information for AD progression. Routine monitoring and targeted interventions to reduce sustained depressive burden may help delay conversion from MCI to AD.</p>","PeriodicalId":14963,"journal":{"name":"Journal of affective disorders","volume":" ","pages":"120066"},"PeriodicalIF":4.9000,"publicationDate":"2025-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Persistent depressive-symptom trajectories predict conversion from mild cognitive impairment to Alzheimer's disease: A longitudinal ADNI study.\",\"authors\":\"Xiahao Ding, Zhiying Zheng, Haitong Wang, Yuanzhen Shao, Shouqiang Zhu, Zhengliang Ma, Xiaoping Gu, Tianjiao Xia\",\"doi\":\"10.1016/j.jad.2025.120066\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Depressive symptoms are increasingly recognized as a modifiable risk factor for Alzheimer's disease (AD). However, most studies have assessed these symptoms at a single time point or within overlapping symptom-outcome windows, limiting temporal inference.</p><p><strong>Methods: </strong>We analyzed 397 participants with baseline mild cognitive impairment (MCI) from the Alzheimer's Disease Neuroimaging Initiative. Depressive symptoms were measured with the 15-item Geriatric Depression Scale (GDS). Group-based trajectory modeling classified symptom courses over the first 36 months. Cox proportional-hazards models estimated the risk of MCI-to-AD conversion over a maximum follow-up of 156 months after the landmark. Restricted cubic spline analysis evaluated the dose-response relationship between 36-month GDS scores and conversion hazard.</p><p><strong>Results: </strong>Three distinct trajectories emerged: persistently low, moderate, and high depressive symptoms. Compared with the low-symptom group, the moderate-symptom group had an adjusted hazard ratio (HR) of 2.36 (95 % CI 1.35-4.13; p = 0.003), and the high-symptom group an HR of 3.79 (95 % CI 1.86-7.69; p < 0.001). A two-group split (low vs. high) produced an adjusted HR of 1.98 (95 % CI 1.25-3.13; p = 0.003). Spline analysis confirmed a linear, dose-response association: each one-point increase in 36-month GDS corresponded to a proportional rise in hazard (p < 0.001).</p><p><strong>Limitations: </strong>The GDS is self-reported and not a clinical diagnosis.</p><p><strong>Conclusions: </strong>Persistently high depressive symptoms over 36 months after MCI diagnosis provide robust prognostic information for AD progression. Routine monitoring and targeted interventions to reduce sustained depressive burden may help delay conversion from MCI to AD.</p>\",\"PeriodicalId\":14963,\"journal\":{\"name\":\"Journal of affective disorders\",\"volume\":\" \",\"pages\":\"120066\"},\"PeriodicalIF\":4.9000,\"publicationDate\":\"2025-12-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of affective disorders\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.jad.2025.120066\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/8/13 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of affective disorders","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jad.2025.120066","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/13 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景:抑郁症状越来越被认为是阿尔茨海默病(AD)的一个可改变的危险因素。然而,大多数研究在单一时间点或在重叠的症状-结果窗口内评估这些症状,限制了时间推断。方法:我们分析了来自阿尔茨海默病神经影像学倡议的397名基线轻度认知障碍(MCI)参与者。采用15项老年抑郁量表(GDS)测量抑郁症状。基于组的轨迹模型对前36个 月的症状过程进行了分类。Cox比例风险模型估计了mci到ad转换的风险,最长随访时间为156 个月。限制性三次样条分析评估了36个月GDS评分与转化风险之间的剂量-反应关系。结果:出现了三种不同的轨迹:持续的低、中、高抑郁症状。与低症状组相比,中度症状组的校正危险比(HR)为2.36(95 % CI 1.35-4.13;p = 0.003),高症状组危险度为3.79(95 % CI 1.86 ~ 7.69;p 局限性:GDS是自我报告的,不是临床诊断。结论:MCI诊断后超过36 个月的持续高抑郁症状为AD进展提供了可靠的预后信息。常规监测和有针对性的干预,以减少持续的抑郁负担可能有助于延迟从轻度认知障碍到阿尔茨海默病的转化。
Persistent depressive-symptom trajectories predict conversion from mild cognitive impairment to Alzheimer's disease: A longitudinal ADNI study.
Background: Depressive symptoms are increasingly recognized as a modifiable risk factor for Alzheimer's disease (AD). However, most studies have assessed these symptoms at a single time point or within overlapping symptom-outcome windows, limiting temporal inference.
Methods: We analyzed 397 participants with baseline mild cognitive impairment (MCI) from the Alzheimer's Disease Neuroimaging Initiative. Depressive symptoms were measured with the 15-item Geriatric Depression Scale (GDS). Group-based trajectory modeling classified symptom courses over the first 36 months. Cox proportional-hazards models estimated the risk of MCI-to-AD conversion over a maximum follow-up of 156 months after the landmark. Restricted cubic spline analysis evaluated the dose-response relationship between 36-month GDS scores and conversion hazard.
Results: Three distinct trajectories emerged: persistently low, moderate, and high depressive symptoms. Compared with the low-symptom group, the moderate-symptom group had an adjusted hazard ratio (HR) of 2.36 (95 % CI 1.35-4.13; p = 0.003), and the high-symptom group an HR of 3.79 (95 % CI 1.86-7.69; p < 0.001). A two-group split (low vs. high) produced an adjusted HR of 1.98 (95 % CI 1.25-3.13; p = 0.003). Spline analysis confirmed a linear, dose-response association: each one-point increase in 36-month GDS corresponded to a proportional rise in hazard (p < 0.001).
Limitations: The GDS is self-reported and not a clinical diagnosis.
Conclusions: Persistently high depressive symptoms over 36 months after MCI diagnosis provide robust prognostic information for AD progression. Routine monitoring and targeted interventions to reduce sustained depressive burden may help delay conversion from MCI to AD.
期刊介绍:
The Journal of Affective Disorders publishes papers concerned with affective disorders in the widest sense: depression, mania, mood spectrum, emotions and personality, anxiety and stress. It is interdisciplinary and aims to bring together different approaches for a diverse readership. Top quality papers will be accepted dealing with any aspect of affective disorders, including neuroimaging, cognitive neurosciences, genetics, molecular biology, experimental and clinical neurosciences, pharmacology, neuroimmunoendocrinology, intervention and treatment trials.